

Kolonkarzinom: Aktueller Stand

Cancer colique: mise au point

Literatur / Références

- 1 Globocan
- 2 Office Fédéral de la Statistique
- 3 Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD et al.: Colorectal cancer screening: clinical guidelines and rationale. *Gastroenterology* 1997;112:594–642.
- 4 Johns LE, Houlston RS: A systematic review and meta-analysis of familial colorectal cancer risk. *Am J Gastroenterol* 2001;96(10):2992–3003.
- 5 Ekblom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer: a population-based study. *N Engl J Med* 1990;323:1228–33.
- 6 Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C: Aspirin and cancer risk: a quantitative review to 2011. *Ann Oncol* 2012;23:1403–15.
- 7 Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;377(9759):31–41.
- 8 Lin KJ, Cheung WY, Yi-Chun Lai J, Giovannucci EL: The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. *Int J Cancer* 2012;130:419–430.
- 9 Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H: Association between vitamin D and risk of colorectal cancer: A systematic review of prospective studies. *J Clin Oncol* 2011;29:3775–82.
- 10 Hewitson P, Glasziou P, Watson E, Towler B, Irwig L: Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): An update. *Am J Gastroenterol* 2008;103:1541–49.
- 11 Shaikat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, Church TR: Long-term mortality after screening for colorectal cancer. *N Engl J Med* 2013;369(12):1106–14.
- 12 Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK: Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: A systematic review and meta-analysis of randomized controlled trials. *PloS Med* 2012;9:e1001352.
- 13 Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR et al.: Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013;369(12):1095–1105.
- 14 Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR et al.: Next-Generation stool DNA test accurately detects colorectal cancer and large adenomas. *Gastroenterology* 2012;142:248–56.
- 15 Lange CP, Campan M, Hinoue T, Schmitz RF, Van der Meulen-de Jong AE, Slingerland H et al.: Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. *PloS One* 2012;7:e50266.
- 16 Lansdorp-Vogelaar I, Von Karsa L: European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition. Introduction. *Endoscopy* 2012;44:SE15–SE30.
- 17 Marbet UA, Regli H. Mourir du cancer colorectal n'est pas une fatalité! Stratégies de prévention du cancer colorectal. *Forum Med Suisse*. 2011;11(13):227–32.
- 18 U S. Preventive Services Task Force. Screening for Colorectal Cancer: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 08–05124–EF-4, October 2008. <http://www.uspreventiveservicestaskforce.org/uspstf08/colocancer/colosum.htm>
- 19 Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM: American college of gastroenterology guidelines for colorectal cancer screening 2008. *Am J Gastroenterol* 2009;104:739–50.
- 20 Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J et al.: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261–68.
- 21 Holalkere NS, Sahani DV, Blake MA, Halpern EF, Hahn PF, Mueller PR: Characterization of small liver lesions: added role of MR after MDCT. *J Comput Assist Tomogr* 2006;30(4):591–96.
- 22 Patel S, McCall M, Ohinmaa A, Bigam D, Dryden DM: Positron Emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: A systematic review. *Ann Surg* 2011;253:666–71.
- 23 Ruers TJ, Wiering B, Van der Sijp JR, Roumen RM, de Jong KP, Comans EF et al.: Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. *J Nucl Med* 2009;50:1036–41.
- 24 Edge SB, Byrd DR, Compton CC, et al.: AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Springer, New York 2010;143–164.
- 25 Ueno H, Mochizuki H, Shimazaki H, Aida S, Hase K, Matsukuma S et al.: Risk factors for an adverse outcome in early invasive colorectal carcinoma. *Gastroenterology* 2004;127(2):385–94.
- 26 Kye BH, Jung JH, Kim HJ, Kang SG, Cho HM, Kim JG: Tumor budding as a risk factor of lymph node metastasis in submucosal invasive T1 colorectal carcinoma: A retrospective study. *BMC Surg* 2012;12:16.

- 27 Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J et al.: Guidelines 2000 for colon and rectal cancer surgery. *J Natl Cancer Inst* 2001;93(8):583–96.
- 28 Bonjer HJ, Hop WC, Nelson H, Sargent DJ, Lacy AM, Guillou PJ et al.: Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. *Arch Surg* 2007;142(3):298–303.
- 29 André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004;350:2343–51.
- 30 André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 2009;27:3109–16.
- 31 Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM: Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *JAMA* 2011;305:2335–42.
- 32 McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E et al.: Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: Findings from the ACCENT database. *J Clin Oncol* 2013;31:2600–07.
- 33 Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T et al.: Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. *J Clin Oncol* 2012;30:3353–60.
- 34 Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. *J Clin Oncol* 2011;29:1261–70.
- 35 Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R et al.: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. *J Natl Cancer Inst* 2011;103:863–75.
- 36 Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y: Survival after resection of multiple hepatic colorectal metastases. *Ann Surg Oncol* 2000;7(9):643–50.
- 37 Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L et al.: Surgical management and outcomes of colorectal cancer liver metastases. *BJS* 2010;97(7):1110–18.
- 38 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008;371:1007–16.
- 39 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al.: Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol* 2013;14(12):1208–15.
- 40 Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Ann Oncol* 2005;16:1311–19.
- 41 Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S et al.: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. *Ann Surg* 2009;249:420–25.
- 42 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
- 43 Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;260:1408–17.
- 44 Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Ann Oncol* 2004;15:460–66.
- 45 Robinson SM, Wilson CH, Burt AD, Manas DM, White SA: Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. *Ann Surg Oncol* 2012;19:4287–99.
- 46 Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. *Ann Surg* 2006;243:1–7.
- 47 Welsh FKS, Tilney HS, Tekkis PP, John TG, Rees M: Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. *Br J Cancer* 2007;96:1037–42.
- 48 Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004;22:229–37.
- 49 Heinemann V, Fischer von Weikersthal L, Decker T, et al.: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) (abstract). *J Clin Oncol* 31,2013(suppl; abstr LBA 3506).
- 50 Stintzing S, Jung A, Rossius L, et al.: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Presented at: European Cancer Congress 2013; September 27–October 1, 2013; Amsterdam, The Netherlands. Abstract LBA17.
- 51 Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al.: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol* 2009;27:672–80.
- 52 Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med* 2009;360:563–72.
- 53 Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M et al.: Can chemotherapy be discontinued in unresectable colorectal cancer? The GERCOR OPTIMO2 study. *J Clin Oncol* 2009;27:5727–34.
- 54 Koopman M, Simkens LHJ, Ten Tije AJ, et al.: Maintenance treatment of capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer: the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG) (abstract). *J Clin Oncol* 31,2013 (suppl; abstr 3502).
- 55 Golberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB et al.: The continuum of care: a paradigm for the management of metastatic colorectal cancer. *The Oncologist* 2007;12:38–50.
- 56 Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–34.

- 57 Oliner KS, Douillard JY, Siena S, Tabernero J, Burkes RL, Barugel ME et al.: Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer. *J Clin Oncol* 2013;31(suppl; abstract 3511).
- 58 Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E et al.: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol* 2013;14:29–37.
- 59 Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T et al.: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol* 2012;30:3499–3506.
- 60 Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al.: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:303–12.